.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ACTT-2 trial evaluated baricitinib plus remdesivir versus remdesivir alone in hospitalized adults with COVID-19. The combination shortened median recovery time and reduced progression to invasive mechanical ventilation or death in the overall study population. The trial was important for demonstrating that targeted immunomodulation can complement antiviral therapy in patients with systemic inflammatory disease. For internists, the practical lesson is that treatment must match disease stage: antiviral therapy is most useful early in the course, while immunomodulation is considered when inflammatory lung disease or oxygen requirement becomes prominent. Baricitinib requires attention to infection risk, thrombosis and kidney function, and treatment should fit evolving local guidance. The study also illustrates why COVID-19 management moved from a single-drug model toward stage-specific combination therapy. The broader principle applies beyond COVID-19: effective treatment of severe viral disease may require simultaneous control of viral replication and dysregulated host inflammation.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ACTT-2 trial evaluated baricitinib plus remdesivir versus remdesivir alone in hospitalized adults with COVID-19. The combination shortened median recovery time and reduced progression to invasive mechanical ventilation or death in the overall study population. The trial was important for demonstrating that targeted immunomodulation can complement antiviral therapy in patients with systemic inflammatory disease. For internists, the practical lesson is that treatment must match disease stage: antiviral therapy is most useful early in the course, while immunomodulation is considered when inflammatory lung disease or oxygen requirement becomes prominent. Baricitinib requires attention to infection risk, thrombosis and kidney function, and treatment should fit evolving local guidance. The study also illustrates why COVID-19 management moved from a single-drug model toward stage-specific combination therapy. The broader principle applies beyond COVID-19: effective treatment of severe viral disease may require simultaneous control of viral replication and dysregulated host inflammation.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
